Art. -Nr.: HY-19855

Copy Link Print Information

AZD-5069

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.91%
CAS. Nr.: 878385-84-3
Formel: C₁₈H₂₂F₂N₄O₅S₂
Molecular Weight:476.52

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

AZD-5069 Chemical Structure

CAS. Nr.: 878385-84-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Clinical Trial
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.

IC₅₀ & Target^[1]

¹²⁵I-IL-8-CXCR2

Alle CXCR Isoform-spezifische Produkte anzeigen :

In Vitro

AZD-5069 (Compound 2) acts as CXCR2 antagonist by inhibition of [¹²⁵I]-IL-8 binding to human CXCR2 receptors and as inhibitor of GROα-induced Ca²⁺ flux in human neutrophils loaded with fluo-3 dye^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 878385-84-3
Appearance Solid
Molecular Weight 476.52
Formel C₁₈H₂₂F₂N₄O₅S₂
Color White to light yellow
SMILES

O=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All In Vivo Efficacy StudyHistological Imaging/StainingRT-PCRWB

Sort by:

Journal Impact Factor

Nat Commun

Pharmacological perturbation of CXCL1 signaling alleviates neuropathogenesis in a model of HEVA71 infection. [Abstract]

2022 Feb 16;13(1):890. PMID: 35173169

AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]

Survival rate and mean clinical score of mice infected with S41 or UI, with or without AZD5069 treatment. For AZD5069 studies, AZD5069 (10 mg/kg) or phosphate-buffered saline (PBS) was administered intracranially at 0, 2 and 4 dpi or intravenously at 0, 2, 4 and 6 dpi following UI or S41 infection in mice (sex undetermined; 25 per group) and monitored for 15 days post infection for survival rates and clinical manifestations.

AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]

Survival rate and mean clinical score of mice infected with S41 or UI, with or without AZD5069 treatment. For AZD5069 studies, AZD5069 (10 mg/kg) or phosphate-buffered saline (PBS) was administered intracranially at 0, 2 and 4 dpi or intravenously at 0, 2, 4 and 6 dpi following UI or S41 infection in mice (sex undetermined; 25 per group) and monitored for 15 days post infection for survival rates and clinical manifestations.

AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]

AZD5069 treatment lowered viral loads in brains of S41-infected mice from 4 to 7 dpi.

AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]

pERK1/2 and ERK1/2 levels were reduced in AZD5069-treated mice.

AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]

Brain lysates of S41- or UI-infected mice with or without AZD5069 treatment were subjected to immunoblotting analyses at 7 dpi. AZD5069 treatment delays the expression of HEVA71 viral proteins. Immunoblot representative of 3 biological repeats is shown.
J Extracell Vesicles

Stromal cell-derived small extracellular vesicles enhance radioresistance of prostate cancer cells via interleukin-8-induced autophagy. [Abstract]

2023 Jul;12(7):e12342. PMID: 37387557
Cell Rep

Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell. [Abstract]

2023 Nov 13;42(11):113424. PMID: 37963015
J Med Chem

Development and Initial Characterization of the First 18F-CXCR2-Targeting Radiotracer for PET Imaging of Neutrophils. [Abstract]

2024 Apr 25;67(8):6327-6343. PMID: 38570909
J Cereb Blood Flow Metab

Neutrophil-derived cathelicidin promotes cerebral angiogenesis after ischemic stroke. [Abstract]

2023 Sep;43(9):1503-1518. PMID: 37194247

AZD-5069 purchased from MedChemExpress. Usage Cited in: J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518. [Abstract]

Quantification of infarct volume and endogenous IgG positive area of mice treated with AZD-5069 (10 mg/kg, icv), JNJ-47965567 and vehicle 7 days after MCAO (n = 6 per group, one-way ANOVA with Bonferroni multiple comparisons test).

AZD-5069 purchased from MedChemExpress. Usage Cited in: J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518. [Abstract]

Representative MAP2 staining of brain infarct and endogenous mouse IgG staining of BBB leakage 7 days after MCAO in mice treated with AZD-5069 (10 mg/kg, icv), JNJ-47965567 or vehicle via ICV injection.
Cancers (Basel)

Radiation-Induced Innate Neutrophil Response in Tumor Is Mediated by the CXCLs/CXCR2 Axis. [Abstract]

2023 Dec 1;15(23):5686. PMID: 38067390
iScience

Microenvironmental signals combine to induce non-additive molecular and phenotypic responses in mammary epithelial cells. [Abstract]

2025 Aug 20;28(9):113407. PMID: 41054517
J Med Microbiol

CXCR2 perturbation promotes Staphylococcus aureus implant-associated infection. [Abstract]

2024 Apr;73(4). PMID: 38567642
bioRxiv

Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection. [Abstract]

2024 Jul 7:2024.07.04.601620. PMID: 39372755
Research Square Preprint

2023 Dec 4.
bioRxiv

2023 Nov 24.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 90 mg/mL (188.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0985 mL

10.4927 mL

20.9855 mL

5 mM

0.4197 mL

2.0985 mL

4.1971 mL

10 mM

0.2099 mL

1.0493 mL

2.0985 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: 2.62 mg/mL (5.50 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 12.5 mg/mL (26.23 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (643 KB)
- English - EN (643 KB)
- Français - FR (643 KB)
- Deutsch - DE (643 KB)
- Norwegian - NO (643 KB)
- Español - ES (643 KB)
- Swedish - SV (643 KB)
- Italian - IT (643 KB)
- Korean - KR (643 KB)
- Portuguese - PT (643 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Norman P, et al. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin Ther Pat. 2013 Jan;23(1):113-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0985 mL	10.4927 mL	20.9855 mL	52.4637 mL
	5 mM	0.4197 mL	2.0985 mL	4.1971 mL	10.4927 mL
	10 mM	0.2099 mL	1.0493 mL	2.0985 mL	5.2464 mL
	15 mM	0.1399 mL	0.6995 mL	1.3990 mL	3.4976 mL
	20 mM	0.1049 mL	0.5246 mL	1.0493 mL	2.6232 mL
	25 mM	0.0839 mL	0.4197 mL	0.8394 mL	2.0985 mL
	30 mM	0.0700 mL	0.3498 mL	0.6995 mL	1.7488 mL
	40 mM	0.0525 mL	0.2623 mL	0.5246 mL	1.3116 mL
	50 mM	0.0420 mL	0.2099 mL	0.4197 mL	1.0493 mL
	60 mM	0.0350 mL	0.1749 mL	0.3498 mL	0.8744 mL
	80 mM	0.0262 mL	0.1312 mL	0.2623 mL	0.6558 mL
	100 mM	0.0210 mL	0.1049 mL	0.2099 mL	0.5246 mL

Keywords

AZD-5069

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AZD-5069

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Small Molecule Immuno-Oncology Compound Library

Drug Repurposing Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Prostate Cancer Compound Library

Chemokine Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) AZD-5069

Alle CXCR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AZD-5069

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Small Molecule Immuno-Oncology Compound Library

Drug Repurposing Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Prostate Cancer Compound Library

Chemokine Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) AZD-5069

Alle CXCR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AZD-5069 Related Classifications

HY-19855 Related Classifications